Table 1.
Clinical characteristics at start of TNFi treatment and changes of outcome measures at follow-up visit (2–8 months) among RA patients overall, and stratified by ACPA status
| Characteristic | Overall RA | ACPA-positive RA | ACPA-negative RA |
|---|---|---|---|
| Number of observations | 867 | 653 | 165 |
| Age, mean | 51.2 | 51.3 | 51.5 |
| Female (%) | 74.1 | 72.1 | 79.2 |
| Baseline values, mean | |||
| DAS28 | 5.0 | 5.0 | 5.0 |
| CRP | 21.0 | 21.9 | 19.1 |
| ESR | 27.9 | 29 | 24.2 |
| SJC | 7.8 | 7.8 | 8.1 |
| TJC | 7.8 | 7.5 | 8.9 |
| VAS global health | 54.1 | 53.8 | 54.5 |
| VAS pain | 53.5 | 53.4 | 53.5 |
| HAQ | 1.0 | 1.0 | 1.0 |
| Changes from baseline to follow-up visit, mean | |||
| ΔDAS28 | –1.5 | –1.5 | –1.6 |
| ΔCRP | –10.2 | –10.4 | –9.3 |
| ΔESR | –9.2 | –9.5 | –8.2 |
| ΔSJC | –4.9 | –4.8 | –5.3 |
| ΔTJC | –4.3 | –4.1 | –4.9 |
| ΔVAS global health | –21.1 | –21.7 | –19.2 |
| ΔVAS pain | –21.6 | –22.3 | –19.7 |
| ΔHAQ | –0.3 | –0.3 | –0.3 |
| EULAR response (%) | |||
| No | 25.2 | 25.6 | 23.6 |
| Moderate | 31.4 | 30.6 | 33.1 |
| Good | 43.4 | 43.8 | 43.3 |
ACPA anti-citrullinated protein/peptide antibodies, DAS28 disease activity score 28, CRP C-reactive protein, ESR erythrocyte sedimentation rate, RA rheumatoid arthritis, SJC swollen joint count, TJC tender joint count, TNFi tumor necrosis factor inhibitor, VAS visual analog scale, HAQ Health Assessment Questionnaire, EULAR European League Against Rheumatism